| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
D-Cysteine hydrochloride does not have a well-defined primary drug target as a free compound. However, it is an important intermediate in the synthesis of the antibiotic cefminox. As a cysteine derivative, it may interact with enzymes involved in cysteine metabolism or oxidative stress pathways. The D-enantiomer of cysteine is less common in nature and may have distinct biological properties compared to L-cysteine. Its antioxidant properties suggest potential targets in oxidative stress-related pathways.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity of D-Cysteine hydrochloride is primarily related to its antioxidant properties. It can scavenge free radicals and protect cells from oxidative damage. As a building block for cefminox, its in vitro antibacterial activity would be associated with the final antibiotic product. Amino acid derivatives like this one are also used as ergogenic supplements. However, the specific in vitro activity of D-Cysteine hydrochloride has not been extensively characterized beyond its antioxidant effects and its role as a synthetic intermediate. |
| ln Vivo |
There is no reported in vivo activity for D-Cysteine hydrochloride as a drug substance. The compound is used primarily as a research chemical and a synthetic intermediate. Its antioxidant properties suggest potential in vivo benefits, but animal studies have not been extensively reported. As a building block for cefminox, its in vivo antibacterial activity would be associated with the final antibiotic product.
|
| Enzyme Assay |
In vitro enzyme assays can be used to study the antioxidant activity of D-Cysteine hydrochloride. A typical protocol involves measuring its ability to scavenge free radicals, such as DPPH or ABTS. In this assay, the compound is incubated with the radical, and the decrease in absorbance is measured. The IC50 value, representing the concentration required to scavenge 50% of the radicals, is determined. This assay is commonly used to evaluate the antioxidant potential of compounds.
|
| Cell Assay |
Cell-based assays for D-Cysteine hydrochloride could focus on its antioxidant and cytoprotective effects. For example, cultured cells could be treated with an oxidative stress inducer (e.g., hydrogen peroxide) in the presence or absence of the compound. Cell viability, reactive oxygen species (ROS) levels, and markers of oxidative damage (e.g., lipid peroxidation) could be measured to assess the compound's protective effects. This assay is commonly used to evaluate the cytoprotective potential of antioxidants.
|
| Animal Protocol |
In vivo animal experiments for D-Cysteine hydrochloride are not commonly performed. However, given its antioxidant properties, it could be tested in animal models of oxidative stress-related diseases. For example, in a mouse model of skin photoaging, mice could be treated topically with the compound, and skin parameters such as wrinkles, hydration, and oxidative stress markers could be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of D-Cysteine hydrochloride have not been well-characterized. As a small molecule (157.62 g/mol), it is likely to be absorbed orally. However, no detailed ADME data are available. The compound's thiol group may undergo metabolism via oxidation or conjugation. Its hydrochloride salt form enhances its aqueous solubility.
|
| Toxicity/Toxicokinetics |
The toxicity profile of D-Cysteine hydrochloride has not been extensively studied. As a research chemical, it is not intended for human use. Standard laboratory safety precautions should be followed. Given its structural similarity to L-cysteine, a natural amino acid, it may have a low toxicity profile. However, specific toxicological information is not available.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-807.
|
| Additional Infomation |
D-Cysteine hydrochloride is a chiral amino acid used in biochemical research and as a synthetic intermediate. It has antioxidant properties and is used in skincare products. It is an important intermediate in the synthesis of the antibiotic cefminox. It is not a drug and has no approved therapeutic indications. The compound is commercially available for research purposes only.
|
| Molecular Formula |
C3H8CLNO2S
|
|---|---|
| Molecular Weight |
157.62
|
| Exact Mass |
156.996
|
| CAS # |
32443-99-5
|
| PubChem CID |
147419
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
293.9ºC at 760 mmHg
|
| Melting Point |
~185 °C (dec.)
|
| Flash Point |
131.5ºC
|
| LogP |
0.83
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
75.3
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@H](C(=O)O)N)S.Cl
|
| InChi Key |
IFQSXNOEEPCSLW-HSHFZTNMSA-N
|
| InChi Code |
InChI=1S/C3H7NO2S.ClH/c4-2(1-7)3(5)6;/h2,7H,1,4H2,(H,5,6);1H/t2-;/m1./s1
|
| Chemical Name |
(2S)-2-amino-3-sulfanylpropanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.3444 mL | 31.7219 mL | 63.4437 mL | |
| 5 mM | 1.2689 mL | 6.3444 mL | 12.6887 mL | |
| 10 mM | 0.6344 mL | 3.1722 mL | 6.3444 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
